Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

GHK-Cu Storage, Stability & Shelf Life: Evidence-Based Handling Guide

By
Published Updated Last reviewed
11 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • FDA-approved GHK-Cu product / none known [1][2]
  • Topical copper peptide serums / sold as cosmetics, which need no FDA approval before sale [3]
  • Injectable compounding / FDA cites immunogenicity risk [4]
  • Compounded drug quality / not reviewed by FDA before marketing [5]

Does GHK-Cu have a standard storage temperature or shelf life?

No. A shelf life is normally set by stability testing of a specific product, and we found no published stability study of GHK-Cu. No FDA-approved drug is known to contain GHK-Cu, so there is no approved label with standardized storage instructions [1][2]. Injectable GHK-Cu is not a cosmetic and is not FDA-approved [3][1]. Copper histidinate (Zycubo) was approved January 12, 2026 for Menkes disease in children and is a different compound, so its label does not apply to GHK-Cu [1][2].

What GHK-Cu is

GHK-Cu is the copper(II) complex of GHK (glycyl-L-histidyl-L-lysine), a tripeptide found in human plasma, saliva and urine [7]. A 2026 systematic review describes the human literature on GHK-Cu as thin and fragmented, with most randomized trials small and run on facial cosmetic creams [6].

What FDA says about compounded GHK-Cu

Non-injectable GHK-Cu is in category 1 of FDA's interim policy for state-licensed pharmacies and physicians, the group under evaluation for the bulks list, and FDA generally does not intend to act against compounders of category 1 substances when its guidance conditions are met [1][10]. FDA has announced it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027; no vote has happened [1]. Injectable GHK-Cu appears in the nominated-but-withdrawn table on FDA's page about bulk substances that may present significant safety risks, with this stated concern: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [4].

Cosmetic and compounded products

Copper peptide serums sold as cosmetics do not need FDA approval before sale [3]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they reach patients [11].

Frequently asked questions

What does FDA say about compounded injectable GHK-Cu?
FDA lists injectable GHK-Cu among bulk substances nominated but withdrawn and states that compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity from aggregation and peptide-related impurities, with limited human data to inform safety considerations [4][1].
Are topical copper peptide serums FDA-approved?
No. Cosmetics and cosmetic ingredients other than color additives do not need FDA approval before sale, and a product making claims to treat disease or change the body's structure or function would legally be a drug [3].
How long does GHK-Cu last once opened or reconstituted?
No published stability study gives a shelf life or in-use period for GHK-Cu, and no FDA-approved GHK-Cu drug label sets one [1][2].
Is GHK-Cu the same as copper histidinate?
No. Copper histidinate (Zycubo) was approved by FDA on January 12, 2026 for Menkes disease in children, and it is a different compound from the copper tripeptide GHK-Cu [1][2].
Is GHK-Cu on FDA's compounding bulks list?
No. Non-injectable GHK-Cu is in category 1 of FDA interim policy for state-licensed pharmacies and physicians, and FDA has announced it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027, with no vote yet [1][10].

References

  1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  2. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  3. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  5. Official web page. Official web page
  6. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials
  7. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
  8. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers
  9. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
  10. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA
  11. Human Drug Compounding Laws | FDA. Human Drug Compounding Laws | FDA
Evidence overview for GHK-Cu Storage, Stability & Shelf Life: Evidence-Based Handling Guide